Basic Information
Renvela ® Tablet 800mg
TABLET, FILM COATED
Regulatory Information
SIN13725P
November 6, 2009
Prescription Only
Therapeutic
ORAL
August 10, 2023
May 30, 2025
XV03AE02
Company Information
Active Ingredients
Strength: 800 mg
Detailed Information
Contraindications
**4\. CONTRAINDICATIONS** Renvela is contraindicated in patients with hypophosphatemia or bowel obstruction. Renvela is contraindicated in patients with hypersensitivity to sevelamer carbonate, sevelamer hydrochloride, or to any of the excipients.
Indication Information
**1\. INDICATIONS AND USAGE** Renvela is indicated for the control of hyperphosphataemia in adult patients receiving hemodialysis or peritoneal dialysis. Renvela is also indicated for the control of hyperphosphataemia in adult patients with chronic kidney disease not on dialysis with serum phosphorus ≥ 1.78 mmol/l. Renvela should be used within the context of a multiple therapeutic approach, which could include calcium supplement, 1,25-dihydroxy Vitamin D3 or one of its analogues to control the development of renal bone disease.